List view / Grid view
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
19 January 2016 | By Victoria White
The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease...
With temperatures regularly reaching -70°C, the coldest place on earth is unsurprisingly the Antarctic. Source BioScience is now able to replicate these bone-chilling temperatures in an innovative, efficient storage solution.
18 January 2016 | By Victoria White
The FDA has accepted for Priority Review Eisai’s supplemental New Drug Application for lenvatinib for the potential treatment of patients with renal cell carcinoma...
18 January 2016 | By Victoria White
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there...
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
18 January 2016 | By Victoria White
In a statement, The University Hospital of Rennes confirmed that five other participants in the clinical trial remain in a stable condition...
18 January 2016 | By Victoria White
Autologous haematopoietic stem cell transplantation (AHSCT), developed at Sheffield Teaching Hospitals, has shown 'remarkable' results in patients with MS...
14 January 2016 | By DiscoveRx
DiscoveRx Corporation announced the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays...
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
14 January 2016 | By
The TERRAIN study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival for enzalutamide compared to bicalutamide...
14 January 2016 | By Victoria White
VAL-083 is a first-in-class small molecule chemotherapy that readily crosses the blood brain barrier...
13 January 2016 | By Victoria White
The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData...
